Investigational Drug Information for GLPG1205
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for GLPG1205?
GLPG1205 is an investigational drug.
There have been 7 clinical trials for GLPG1205.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2014.
The most common disease conditions in clinical trials are Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonias, and Fibrosis. The leading clinical trial sponsors are Galapagos NV and [disabled in preview].
There are seven US patents protecting this investigational drug and one hundred and twenty international patents.
Summary for GLPG1205
| US Patents | 7 |
| International Patents | 120 |
| US Patent Applications | 25 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 2 (2014-12-01) |
| Vendors | 13 |
Recent Clinical Trials for GLPG1205
| Title | Sponsor | Phase |
|---|---|---|
| Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205 | Galapagos NV | Phase 1 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects | Galapagos NV | Phase 1 |
| A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) | Galapagos NV | Phase 2 |
Clinical Trial Summary for GLPG1205
Top disease conditions for GLPG1205
Top clinical trial sponsors for GLPG1205
US Patents for GLPG1205
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GLPG1205 | See Plans and Pricing | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (Mechelen, BE) | See Plans and Pricing |
| GLPG1205 | See Plans and Pricing | Pyrrolo[1,2-b]pyridazine derivatives | Gilead Sciences, Inc. (Foster City, CA) | See Plans and Pricing |
| GLPG1205 | See Plans and Pricing | 2-oxindole compounds | ChemoCentryx, Inc. (Mountain View, CA) | See Plans and Pricing |
| GLPG1205 | See Plans and Pricing | 2-oxindole compounds | ChemoCentryx, Inc. (Mountain View, CA) | See Plans and Pricing |
| GLPG1205 | See Plans and Pricing | Pyrrolo[1,2-B]pyridazine derivatives | Gilead Sciences, Inc. (Foster City, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GLPG1205
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GLPG1205 | Argentina | AR089284 | 2031-12-22 | See Plans and Pricing |
| GLPG1205 | Australia | AU2012357067 | 2031-12-22 | See Plans and Pricing |
| GLPG1205 | Brazil | BR112014015142 | 2031-12-22 | See Plans and Pricing |
| GLPG1205 | Canada | CA2859578 | 2031-12-22 | See Plans and Pricing |
| GLPG1205 | Chile | CL2014001664 | 2031-12-22 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
